PLoS ONE (Oct 2010)

Tamoxifen-independent recombination in the RIP-CreER mouse.

  • Yanmei Liu,
  • Jakob Suckale,
  • Jimmy Masjkur,
  • Maria Grazia Magro,
  • Anja Steffen,
  • Konstantinos Anastassiadis,
  • Michele Solimena

DOI
https://doi.org/10.1371/journal.pone.0013533
Journal volume & issue
Vol. 5, no. 10
p. e13533

Abstract

Read online

BackgroundThe inducible Cre-lox system is a valuable tool to study gene function in a spatial and time restricted fashion in mouse models. This strategy relies on the limited background activity of the modified Cre recombinase (CreER) in the absence of its inducer, the competitive estrogen receptor ligand, tamoxifen. The RIP-CreER mouse (Tg (Ins2-cre/Esr1) 1Dam) is among the few available β-cell specific CreER mouse lines and thus it has been often used to manipulate gene expression in the insulin-producing cells of the endocrine pancreas.Principal findingsHere, we report the detection of tamoxifen-independent Cre activity as early as 2 months of age in RIP-CreER mice crossed with three distinct reporter strains.SignificanceEvidence of Cre-mediated recombination of floxed alleles even in the absence of tamoxifen administration should warrant cautious use of this mouse for the study of pancreatic β-cells.